Core Viewpoint - The article discusses the rising trend of mergers and acquisitions (M&A) in the investment sector, emphasizing the concept of "differentiated pricing" in transactions, particularly in the context of the acquisition of Pengli Bio by Aopumai [2][3][9]. Group 1: M&A Trends - The investment community is increasingly referring to a "golden age of M&A," driven by a return to reasonable asset valuations and supportive government policies [2][3]. - Aopumai's acquisition of Pengli Bio exemplifies this trend, with the final transaction price set at approximately 1.451 billion yuan, reflecting a significant discount compared to previous valuations [2][9]. Group 2: Differentiated Pricing - The concept of "differentiated pricing" is becoming more common in M&A transactions, allowing for tailored exit strategies for various investors involved in the target company [3][5]. - Aopumai's acquisition involved setting four different pricing tiers for the investors in Pengli Bio, ranging from 1.24 billion yuan to 2.18 billion yuan, showcasing the flexibility in structuring deals [4][12]. Group 3: Case Studies - The article references other similar cases, such as Zhaoyi Innovation's acquisition of Saixin Electronics, which also employed differentiated pricing strategies [5][14]. - The acquisition of Pengli Bio is highlighted as a typical case, with its history of rapid valuation increases followed by a significant discount during the acquisition process [9][10]. Group 4: Market Implications - The article suggests that M&A activities are a means to alleviate market bubbles and provide liquidity to investors who have been trapped in illiquid positions due to a cooling IPO market [11][12]. - The involvement of various institutional investors in Pengli Bio's funding rounds indicates a complex ownership structure, which adds layers of negotiation in M&A transactions [13][10]. Group 5: Future Outlook - The trend of differentiated pricing is expected to continue growing in the M&A landscape, as it provides a practical tool for achieving consensus among diverse stakeholders [6][18]. - The article concludes that the M&A market is likely to remain active, driven by the need for capital flow and the resolution of complex ownership structures in target companies [19][20].

将投中网设为"星标⭐"，第一时间收获最新推送 并购流行起"差异化对价"。 作者丨蒲凡 编辑丨张楠 来源丨 投中网 最近一年，投资圈越来越流行"并购进入黄金时代"的说法。人们给出的理由主要有两个，一个是目前距离美元大放水时代已经整整过去了4年，创业者们 不再抱有幻想、投资人们没有了耐心，优质资产纷纷回到一个合理的估值区间，是抄底的好窗口；另一个是新"国九条""科创板八条"等一系列政策出 台，赋予了"并购"前所未有的正面定性，买方数量将大大增加。 近日，上海奥浦迈生物科技股份有限公司（以下简称"奥浦迈"）宣布将收购澎立生物医药技术（上海）股份有限公司（以下简称"澎立生物"）。交易对 手除了澎立生物实控人JIFENG DUAN控制的实体外，均是澎立生物的外部投资机构。经奥浦迈与交易对方充分协商，澎立生物100%股权的最终交易总 价约为14.51亿元。 这笔交易再一次复现了2023年底，歌尔股份收购驭光科技的操作，即相比最后一轮融资，收购折价近半。根据奥浦迈发布的公告， 澎立生物用2年半时 间完成了估值1460%的倍增，又在3年后出现了55%的折价，过程中"欲IPO而不得"，最终被一家营收规模、净利润都未明显强于自己 ...